Clinical Trials Browser

Biliary Tract Neoplasms × Infusions, Intravenous × 90 days × Clear all

NCT07530445 2026-04-15

Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer

Phase 2 Recruiting

Gastrointestinal

Biliary Tract Neoplasms